European Growth Stocks With Strong Insider Confidence

As the European market navigates a landscape of mixed stock index performances and ongoing trade discussions with the U.S., investors are increasingly attentive to companies that demonstrate robust growth potential. In this context, stocks characterized by high insider ownership often signal strong confidence from those closest to the company's operations, making them compelling options for those seeking growth opportunities in uncertain times.

Top 10 Growth Companies With High Insider Ownership In Europe

Name	Insider Ownership	Earnings Growth
Xbrane Biopharma (OM:XBRANE)	21.8%	56.8%
Pharma Mar (BME:PHM)	11.8%	43.3%
MedinCell (ENXTPA:MEDCL)	13.9%	130.8%
Marinomed Biotech (WBAG:MARI)	29.7%	20.2%
KebNi (OM:KEBNI B)	38.3%	94.5%
Elliptic Laboratories (OB:ELABS)	24.4%	79%
CTT Systems (OM:CTT)	17.5%	37.9%
Circus (XTRA:CA1)	24.7%	94.8%
Bonesupport Holding (OM:BONEX)	10.4%	62.3%
Bergen Carbon Solutions (OB:BCS)	12%	63.2%

Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Basic-Fit (ENXTAM:BFIT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Basic-Fit N.V., with a market cap of €1.74 billion, operates fitness clubs through its subsidiaries.

Operations: The company generates revenue from its fitness clubs primarily in two segments: €522.10 million from the Benelux region and €693.10 million from France, Spain, and Germany.

Insider Ownership: 12%

Basic-Fit demonstrates potential as a growth company with high insider ownership, evidenced by more shares being bought than sold by insiders recently. Its earnings are forecast to grow significantly at 61.9% annually, outpacing the Dutch market's 9.3%. However, revenue growth is slower at 9.3%, and financial results are impacted by large one-off items. While it became profitable this year and shows high return on equity projections, interest payments aren't well covered by earnings.

• Click here to discover the nuances of Basic-Fit with our detailed analytical future growth report.
• Our valuation report unveils the possibility Basic-Fit's shares may be trading at a premium.

P/F Bakkafrost (OB:BAKKA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: P/F Bakkafrost, along with its subsidiaries, is engaged in the production and sale of salmon products across North America, Western Europe, Eastern Europe, Asia, and other international markets, with a market cap of NOK24.98 billion.

Operations: The company's revenue segments include Sales and Other at DKK10.32 billion, Farming Faroe Islands at DKK3.96 billion, Fishmeal, Oil and Feed at DKK2.48 billion, Farming Scotland at DKK1.73 billion, Services at DKK855.10 million, Freshwater Faroe Islands at DKK838.45 million, and Freshwater Scotland at DKK102.24 million.

Insider Ownership: 16.2%

P/F Bakkafrost exhibits strong growth potential with earnings expected to grow significantly at 56.8% annually, surpassing the Norwegian market's 10.3%. Despite revenue growth of 15% being slower than earnings, it remains above the market average. Recent financial results show a net loss and decreased profit margins, highlighting challenges. The stock is trading well below its estimated fair value, suggesting possible upside as analysts predict a price rise of over 40%.

• Unlock comprehensive insights into our analysis of P/F Bakkafrost stock in this growth report.
• The valuation report we've compiled suggests that P/F Bakkafrost's current price could be quite moderate.

Redcare Pharmacy (XTRA:RDC)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Redcare Pharmacy NV operates as an online pharmacy across several European countries, including the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France; it has a market cap of approximately €2.12 billion.

Operations: The company generates revenue through its DACH segment, amounting to €2.06 billion, and its International segment, which contributes €464.53 million.

Insider Ownership: 13.4%

Redcare Pharmacy demonstrates promising growth, with earnings projected to increase by 54.27% annually and revenue growing at 15.8%, outpacing the German market. Insiders have shown confidence by buying shares recently, and no substantial sales occurred in the past three months. The stock trades significantly below its estimated fair value, indicating potential undervaluation. Regulatory developments secure its position in the German e-prescription market, bolstering future growth prospects despite current net losses.

• Get an in-depth perspective on Redcare Pharmacy's performance by reading our analyst estimates report here.
• According our valuation report, there's an indication that Redcare Pharmacy's share price might be on the expensive side.

Make It Happen

• Explore the 214 names from our Fast Growing European Companies With High Insider Ownership screener here.
• Searching for a Fresh Perspective? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com